Diagnosis of Prostate Cancer: A Comparative Evaluation of Biological Techniques

Abstract

Prostate cancer (PCa) is the most prevalent cause of cancer-related deaths worldwide. This review aims to synthesize the contemporary literature (2018–2026) on various diagnostic approaches of PCa for clinicians. Currently, the standard approach to PCa diagnosis includes (1) prostate-specific antigen (PSA) testing, (2) its derivatives, and (3) digital rectal examination (DRE). This approach is readily available and cost-effective but lacks specificity, thus resulting in a high incidence of overdiagnosis and overtreatment of PCa patients. This review aims to compare the traditional approaches with the newly developed approaches to PCa diagnosis and investigate their suitability for research purposes, including urine-based markers, liquid biopsy, and histopathology. Each of these approaches has advantages and disadvantages. Advanced imaging techniques like multiparametric magnetic resonance imaging (mpMRI) are helpful in the localization of PCa and can prevent unnecessary biopsies. Histopathology remains the gold standard in the confirmation of PCa diagnosis. Newly developed blood-based markers and advanced imaging techniques are more sensitive and specific in the diagnosis of PCa and are likely to result in a better clinical outcome than the traditional approaches. However, the cost of these approaches remains a global challenge in developing and developed countries alike. PCa diagnosis tools and strategies are presented in a clinical and cost-effective manner and are integrated in a tiered approach with the aim of controlling and managing PCa and its diagnosis.